KyungDong Pharm home
Prescription Medicines

Aclova Tab.

Product Category
antiviral drugs
Active Ingredients
acyclovir
Appearance
Light blue round tablet
Reimbursement Code
648101520
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Acyclovir (in-house specification) ---- 200mg
- Additive (tar color aluminum lake): Blue No. 2
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: microcrystalline cellulose, magnesium stearate, silicon dioxide, sodium starch glycolate, povidone K30

2. Effectiveness
1. Treatment and prevention of herpes simplex virus infections of skin and mucous membranes, including primary and recurrent genital herpes
2. It is effective in treating herpes zoster virus infection, especially acute pain. On the other hand, its effectiveness for postherpetic neuralgia has not yet been proven.
3. Treatment of chickenpox in children over 2 years of age

3. Dosage and dosage
○ Adult
1. Treatment of herpes simplex virus infection
1) Acyclovir is administered 5 times a day, 200 mg once, at 4-hour intervals for 5 days. In case of severe primary infection, treatment can be extended.
2) For patients with severe immune dysfunction (after bone marrow transplant, etc.) or patients with digestive tract malabsorption, the single dose can be increased to 400 mg or the administration route can be changed to intravenous injection.
3) It is advisable to administer as soon as possible after infection, and in case of relapse, it is advisable to administer when prodromal symptoms or lesions first appear.

2. Prevention of herpes simplex infection in patients with normal immune function
1) Administer this drug 4 times a day, 200 mg once, at approximately 6-hour intervals. Alternatively, it can be administered twice a day, 400 mg once, at 12-hour intervals.
2) Afterwards, the dose may be reduced to 200 mg at a time, 2 to 3 times a day, after confirming its effectiveness.
3) In order to check the natural change process of the disease, long-term treatment patients should periodically discontinue treatment every 6 to 12 months to check.

3. Prevention of herpes simplex infection in patients with weakened immune function
1) This drug is administered 4 times a day, 200 mg each time, at approximately 6-hour intervals.
2) For patients with severe immune dysfunction (such as after bone marrow transplantation) or digestive system malabsorption, the single dose can be increased to 400 mg or the administration route can be changed to intravenous injection.
3) Administer during the period of infection risk.

4. Treatment of shingles infection
1) This drug is administered 5 times a day, 800 mg once, at approximately 4-hour intervals, excluding bedtime, for a total of 7 days.
2) For patients with severe immune dysfunction or digestive system malabsorption, intravenous administration should be considered.
3) It is best to administer it as soon as possible after infection, and the sooner it is treated, the better the effect.

○ Children
1. Treatment of herpes simplex infection and prevention of herpes simplex infection in patients with weakened immune function
1) 2 years or older: Same as adults.
2) Under 2 years of age: Administer 1/2 of the adult dose.
3) There is still no clear data on the prevention of herpes simplex virus infection in patients with normal immune function.

2. Treatment of chickenpox in children over 2 years of age: Administer this drug at a dose of 20 mg per kg of body weight (maximum 800 mg per time), 4 times a day for 5 days.
Treatment is better the sooner the chickenpox rash appears, preferably within 24 hours after the rash.

○ Patients with renal impairment
Patients with renal impairment are prone to mental and nervous system side effects, so caution should be exercised, such as extending the administration interval or reducing the dose.
1. Treatment of herpes simplex infection
The oral dose is usually not higher than the cumulative dose resulting from intravenous administration. However, for patients with severe renal impairment (creatinine clearance less than 10 mL per minute), it is recommended to administer 200 mg of this drug every 12 hours.

2. Treatment of shingles virus infection
For patients with severe renal impairment (creatinine clearance less than 10 mL per minute), it is recommended to administer this drug at a dose of 800 mg 3 to 4 times a day, at approximately 6 to 8 hour intervals.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug or its components or valacyclovir
2) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

2. Administer with caution to the following patients.
1) Patients with renal impairment (adverse mental and nervous system reactions are likely to occur)
2) Patients with liver failure (liver function is likely to worsen)
3) Infants, toddlers, children
4) Elderly people

3. Adverse reactions
1) Shock: In rare cases, anaphylactic shock or anaphylactic-like reactions may occur, so observe thoroughly. If symptoms such as a drop in blood pressure, difficulty breathing, or chest tightness appear, immediately stop administration and take appropriate measures.
2) Hypersensitivity reaction: Photosensitivity reaction and fixation may occur. If these symptoms appear, take appropriate measures, such as discontinuing administration. Occasionally, rash, fever, blisters, urticaria-like erythema, and hives may appear.
3) Skin: Alopecia, erythema multiforme, cutaneous mucous membrane syndrome (Stevens-Johnson syndrome), and toxic epidermal necrolysis (Riel syndrome) may occur.
4) Mental nervous system: Disorder of consciousness, disorientation, difficulty concentrating, aggressive behavior, depersonalization, agitation, incoordination, coma, confusion, delirium, stuttering, encephalopathy, hallucinations, psychosis, convulsions, drowsiness, tremors, excitement, forgetfulness, insomnia, anxiety, self-talk, abnormal sensations, ataxia, inability to walk, involuntary movements, nystagmus, rarely tremors, drowsiness, dizziness. This symptom appears more often in the elderly or those with renal impairment.
5) Kidney: Renal failure, crystalluria, sometimes elevated BUN and serum creatinine, rarely hematuria, proteinuria, urinary red blood cell casts, and pyuria may occur.
6) Blood and lymphatic system: leukocytoclastic angiitis, lymphadenopathy, hemorrhage, purpura, occasionally anemia, decreased or increased white blood cells, increased eosinophils, rarely increased lymphocytes, increased platelets, decreased granulocytes, decreased platelets, and increased basophils.
7) Liver: Hepatitis, liver failure, jaundice, sometimes abnormalities in liver function tests (AST/ALT, LDH, ALP, increased total bilirubin), and hepatomegaly may occur.
8) Digestive system: Gastritis, thirst, constipation, acute pancreatitis, sometimes diarrhea, loose stools, epigastric pain, stomach pain, abdominal pain, nausea, vomiting, and in rare cases, indigestion, loss of appetite, and glossitis may occur. If these symptoms appear, take appropriate measures, such as discontinuing administration.
9) Whole body: Fever, extremity edema, syncope, pallor, muscle weakness, weakness, sometimes general malaise, and headache may occur.
10) Musculoskeletal system: Joint pain and muscle pain may occur.
11) Circulatory system: Arrhythmia, chest pain, increased blood pressure, decreased blood pressure, tachycardia, and in rare cases, palpitations may occur.
12) Urinary system: Urinary obstruction and, in rare cases, difficulty urinating may occur.
13) Others: Urinary sugar, pneumonia, pharyngitis, difficulty breathing, pleural effusion, pain, hearing loss, conjunctivitis, visual abnormality, taste disorder, hair loss, sweating, hyponatremia, decreased serum protein, sometimes increased total cholesterol level, triglyceride level, and serum potassium level, and rarely, decreased serum albumin level.

4. General precautions
1) If symptoms do not improve or worsen after 5 days of treatment for herpes simplex and chickenpox, or 7 days for herpes zoster, a different treatment method should be used.
2) This drug is most effective when administered as early as possible in the onset of the disease, so treatment of shingles should be started within 5 days after skin symptoms appear, and treatment of chickenpox should be started within 3 days of skin symptoms appearing.
3) When treating patients with impaired immune function, the use of intravenous drugs should be considered.
4) During the administration of this drug (especially when administering high doses), sufficient fluid intake is necessary to prevent dehydration and reduce the risk of nephrotoxicity.
5) Recurrent genital herpes treatment is intended for patients who have repeated outbreaks of genital herpes (immune-competent patients, patients who have had genital herpes recurrently at least 6 times or more). After taking this drug for 1 year, it should be considered whether to continue taking it.
6) Since consciousness disorders, etc. may occur, thoroughly explain to the patient that he or she should be careful when operating machinery that carries risks, such as driving a car. Additionally, patients with renal impairment are particularly prone to disorders of consciousness, so caution must be taken depending on the patient's condition.

5. Interaction
1) It has been reported that the combined use of probenecid and this drug injection extends the average half-life of this drug by 18%, increases the area of the plasma-concentration curve by 40%, and reduces urinary excretion and renal clearance.
2) Any drug that affects renal function can substantially affect the pharmacokinetics of acyclovir and may increase the risk of renal impairment when combined with nephrotoxic drugs.
3) It has been reported that cimetidine reduces the urinary excretion of this drug and increases the area of the plasma-concentration curve by 27%.
4) When theophylline and this drug are used together, symptoms of theophylline poisoning may appear.
5) It has been reported that the combined use of mycophenolate mofetil and this drug reduces the excretion of mycophenolate mofetil metabolites and increases the area of the plasma-concentration curve of both drugs.

6. Administration to pregnant and lactating women
1) As teratogenic effects have been reported as a result of animal testing, it should be administered to pregnant women or women who may be pregnant only when the benefits of treatment are judged to outweigh the risks.
2) Since the ingredients of this medicine are passed into breast milk, breast-feeding should be discontinued during treatment.

7. Administration to children
For infants, toddlers, and children, administer with caution, limiting use to the minimum necessary. In particular, safety for newborns and low birth weight infants has not been established, so it is administered only when the therapeutic benefits are judged to outweigh the risks.

8. Administration to elderly people
This drug is mainly excreted through the kidneys. Elderly people often have reduced renal function, so there is a risk that high blood levels will persist and adverse reactions are likely to occur. Therefore, administer with caution, paying attention to the dosage and administration interval. Also, provide sufficient moisture during administration.

9. Treatment in case of overdose
1) In cases where 20 g of this drug was taken at a time, agitation, lethargy, convulsions, and lethargy were reported as adverse reactions during overdose. In case of overdose, this drug may precipitate in the renal tubules, causing an increase in BUN/Cr and renal failure. In case of excessive intravenous administration, confusion, hallucinations, excitement, epileptic seizures, and coma may occur.
2) In case of overdose, the blood concentration of this drug should be measured while carefully observing the patient's condition. If symptoms of overdose appear, hemodialysis may be considered to lower the blood concentration of this drug.

10. Other
1) In a bone marrow micronucleus experiment, it was reported that chromosomal abnormalities may be induced when high doses (180 mg/kg or more) are administered intraperitoneally to mice.
2) Several recent studies have shown that this drug causes mutations and reduced spermatogenesis when administered in high doses. However, in human studies within the recommended dose range, there was no effect on sperm count.

5. How to save
Store at room temperature

6. Packaging unit
30 tablets/bottle, 100 tablets/bottle

7. Expiration date
36 months from date of manufacture

Product Updates

Total 4items

No.Product NameDetailsDate of ChangeDownload
4Aclova Tab.Precautions for use2026.04.28PDF0001_198601102_Precautions for use (Ecrova tablets 200mg).pdf
3Aclova Tab.Ecrovar tablets (efficacy, dosage, usage, precautions...2018.07.02PDFEcrovar tablets.pdf
2Aclova Tab.Ecrovar tablets 200mg (Precautions for use)2008.01.02HWP9-2. Ecrovar Tablet (Precautions for use) (2008.01.02).hwp
1Aclova Tab.Ecrovar tablets 200mg (Precautions for use)2009.10.07HWP9-1. Ecrovar tablets (precautions for use) (2009.10.07).hwp